FDA, Health Outcomes and Patient Advocacy - Health Care Compliance Brief

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

FDA

Health Outcomes

Patient Advocacy

How the Life Sciences Industry Can Boost Diversity and Inclusion Efforts

HIT Consultant

MAY 2, 2022

Although it is well established that diversity improves outcomes and drives excellence, implementing diversity lags behind in many industries, including life sciences and healthcare. experience significant health disparities , including higher rates of chronic disease and premature death compared to the white population.

COVID-19 Vaccine

COVID-19 Vaccine COVID-19 Patient Advocacy Pharmaceutical Industry

TAKE TWO: CMS’s Second Attempt to Streamline Breakthrough Device Coverage Limited to 5 Devices Per Year

Health Law Advisor

JULY 21, 2023

Food and Drug Administration (FDA) as breakthrough devices. [1] Among other factors, Medicare NCDs rely heavily on health outcomes data—particularly with regard to Medicare beneficiaries—to determine whether a device would be “reasonable and necessary.” [5]

FDA

FDA Medicare Medicare Patient Advocacy

How the Life Sciences Industry Can Boost Diversity and Inclusion Efforts

TAKE TWO: CMS’s Second Attempt to Streamline Breakthrough Device Coverage Limited to 5 Devices Per Year

Stay Connected